

## Supplementary Information

### Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients

Sebastian F. Mause\*<sup>1</sup>, Annika Deck<sup>1</sup>, Mark Hennies<sup>2</sup>, Nadine Kaesler<sup>3</sup>, Pieter Evenepoel<sup>4</sup>, William A. Boisvert<sup>5</sup>, Ulf Janssen<sup>#,6</sup>, Vincent M. Brandenburg<sup>#,1</sup>

<sup>1</sup>Department of Cardiology, University Hospital of the RWTH Aachen, Germany

<sup>2</sup>TECOmedical AG, Sissach, Switzerland

<sup>3</sup>Department of Nephrology, University Hospital of the RWTH Aachen, Aachen, Germany

<sup>4</sup>Department of Medicine, University Hospital Leuven, Leuven, Belgium

<sup>5</sup>Center for Cardiovascular Research, John A. Burns School of Medicine, University of Hawaii, Honolulu, USA

<sup>6</sup>Department of Nephrology, Klinikum Maria-Hilf, Mönchengladbach, Germany

# These authors contributed equally to this work

\* *Corresponding author*: Sebastian F. Mause, MD, Department of Cardiology, Pauwelsstraße 30, D - 52074 Aachen, University Hospital RWTH Aachen, Germany; Phone: +49 (0)241/80 35223; Fax: +49 (0)241/80 82446; Email: smause@ukaachen.de

*Submitted*: March 25, 2016; *Revised*: March 30, 2016; *Accepted*: March 31, 2016; *Published*: March 31, 2016;

*Citation*: Mause SF, Deck A, Hennies M, Kaesler N, Evenepoel P, Janssen U, Brandenburg VM. Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients. *Discoveries* 2016, January-March; 4(1): e55. DOI: 10.15190/d.2016.2

**Supplementary Table 1:** Clinical characteristics of the study population (n=12).


	mean	SD
<b>age (years)</b>	66.6	9.1
<b>dialysis vintage (months)</b>	54.1	50.0
<b>incidence of diabetes</b>	50%	
<b>hemoglobin (g/L)</b>	115	15
<b>calcium (mval/L)</b>	3.97	0.43
<b>phosphate (mg/dL)</b>	4.50	1.42
<b>AP (U/L)</b>	188	191
<b>iPTH (pg/mL)</b>	483	590
<b>25-OH-Vit. D3 (ng/mL)</b>	16.0	7.2
<b>1,25-Dihydroxy-Vit. D3 (ng/mL)</b>	20.1	10.2
<b>albumin (g/dL)</b>	4.07	0.61

**Supplementary Table 2:**

Synopsis of technical characteristics of the Biomedica and TECOmedical ELISA.

	<b>Biomedica</b>	<b>TECOmedical</b>
<b>Suggested sample type</b>	serum, heparin plasma, EDTA plasma	serum, heparin plasma, EDTA plasma
<b>Sensitivity</b>	LOD: 0.073 ng/mL; LLOQ: < 0.170 ng/mL	LOD: 0.009 ng/mL; LLOQ: 0.058 ng/mL
<b>Standard range</b>	0.34 – 5.5 ng/mL	0.05 - 3.0 ng/mL
<b>Plate coating</b>	goat anti-human polyclonal sclerostin Ab	streptavidin
<b>Antibodies</b>	biotin-labeled mouse anti-human monoclonal sclerostin Ab	biotin-labeled goat anti-human polyclonal sclerostin Ab + HRP-conjugated anti-human monoclonal sclerostin Ab
<b>Conjugate</b>	streptavidin-HRPO	
<b>Substrate</b>	tetramethylbenzidine	tetramethylbenzidine
<b>Incubation time</b>	18-24 h / 1 h / 30 min	4 h / 30 min
<b>Incubation temperature</b>	room temperature	room temperature

**Supplementary Figure 1:** Dilution recovery (%) in various sample types as indicated and assessed with the Biomedica (black) and TECOmedical (grey) ELISA.



**Supplementary Figure 2:** Spike recovery (%) in various sample types as indicated and assessed with the Biomedica (black) and TECOmedical (grey) ELISA.

